Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
N02CD03
|
| gptkbp:developedBy |
gptkb:Amgen
gptkb:Novartis |
| gptkbp:drugClass |
gptkb:monoclonal_antibody
|
| gptkbp:form |
pre-filled syringe
140 mg 70 mg pre-filled autoinjector |
| gptkbp:genericName |
gptkb:erenumab
|
| gptkbp:halfLife |
28 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aimovig
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Amgen
gptkb:Novartis |
| gptkbp:mechanismOfAction |
CGRP receptor antagonist
|
| gptkbp:notRecommendedFor |
pregnant women
breastfeeding women children under 18 |
| gptkbp:pregnancyCategory |
Not recommended
|
| gptkbp:prescribes |
adults
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
constipation
muscle cramps injection site reactions |
| gptkbp:target |
calcitonin gene-related peptide receptor
|
| gptkbp:usedFor |
migraine prevention
|
| gptkbp:bfsParent |
gptkb:Amgen
|
| gptkbp:bfsLayer |
6
|